Market research
RTI.F Revance Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 368M
- P/E ratio
- 0.0
- Analyst target
- 39.78
- Dividend yield
- Not available
- Beta
- 0.95
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US7613301099
- Market cap
- 368M
- P/E ratio
- 0.0
- Analyst target
- 39.78
- Dividend yield
- Not available
- Beta
- 0.95
About
About Revance Therapeutics, Inc
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. As of February 6, 2025, Revance Therapeutics, Inc. operates as a subsidiary of Crown Laboratories, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RTI.F discussion.
5 years, 5 months ago
Revance Therapeutics, Inc is currently in a long term uptrend where the price is trading 18.1% above its 200 day moving average.
From a valuation standpoint, the stock is 91.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 107.4.
Revance Therapeutics, Inc's total revenue rose by 12409.0% to $11M since the same quarter in the previous year.
Its net income has dropped by 72.8% to $-78M since the same quarter in the previous year.
Finally, its free cash flow fell by 90.9% to $-65M since the same quarter in the previous year.
Based on the above factors, Revance Therapeutics, Inc gets an overall score of 3/5.